Enveda Biosciences has secured $55m in a Series B2 financing round to expedite its platform and advance multiple candidates to clinical trials.
The latest funding adds to the $119m secured in combin… [+2486 chars]
With the closure of the Series B2 round, Enveda's total capital raised stands at $230m.
